Skip to main content
HCPCS J3304 · Level II · Part B drug

J3304: triamcinolone acetonide (Zilretta), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J3304

Billing unit
1 MG
Inj triamcinolone ace xr 1mg
ASP payment limit
$19.159
October 2026; -0.6% vs July 2026
Practitioner MUE
64
MAI 2
OPPS status
SI K
APC 9469
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J3304 is the Level II code for Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $19.159 per billing unit, down 0.6% from July 2026. The practitioner MUE allows up to 64 units per date of service (MAI 2), so a full 64-unit day is $1,226.18 at the current limit. Under OPPS it carries status indicator K in APC 9469. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names triamcinolone acetonide: J3300 (Triesence from Harrow Eye, LLC); J3299 (Xipere from Bausch & Lomb Americas Inc); J3301 (not otherwise specified (for products without their own code); billed per 10 mg). The ASP crosswalk maps 1 NDC to it, sold as Zilretta by Pacira Pharmaceuticals, Inc. No current Billing and Coding Article lists J3304, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J3304 at $19.159 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $19.28 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J3304
QuarterPayment limitPerCoinsurance
October 2026$19.1591 MG20%
July 2026$19.281 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J3304. Report the NDC in the claim's drug segment and bill the number of J3304 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J3304
NDCDrug nameLabelerPackage sizeBilling units / package
65250-0003-01ZilrettaPacira Pharmaceuticals, Inc.1 × 132

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for J3304. For practitioners the limit is 64 units per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.

MUE values for J3304 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services642 Date of Service Edit: PolicyAnatomic Consideration
Facility outpatient hospital642 Date of Service Edit: PolicyAnatomic Consideration

MUE for J3304 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J3304 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J3304 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J3304 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J3304 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J3304 carries status indicator K and is assigned to APC 9469, with a published national unadjusted payment of $19.159. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J3304 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $19.16 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J3304 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J3304

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J3304

What does HCPCS code J3304 describe?

J3304 is defined by CMS as "Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J3304 a CPT code?

No. J3304 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as triamcinolone acetonide (Zilretta); CPT codes are five-character codes maintained by the AMA. On a Part B claim J3304 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J3304 in October 2026?

The ASP-based payment limit is $19.159 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $19.28. Commercial payers use their own fee schedules.

How many units of J3304 can be billed per day?

The practitioner Medically Unlikely Edit is 64 units per date of service with adjudication indicator 2 (Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Anatomic Consideration" as the rationale.

Which NDCs map to J3304?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Zilretta (Pacira Pharmaceuticals, Inc.). For example NDC 65250-0003-01 (package size 1) equals 32 billing units of J3304.

Does J3304 have NCCI bundling edits?

No active practitioner PTP pairs list J3304 as a column-1 or column-2 code in the v323r0 release.

J3304 vs J3300: what is the difference?

Both are HCPCS Level II codes whose descriptor names triamcinolone acetonide. What sets J3300 apart: Triesence from Harrow Eye, LLC. J3304 is billed per 1 mg, limit $19.159, MUE 64; J3300 is billed per 1 mg, limit $17.199, MUE 80. Report the code whose descriptor matches the product and setting in the record.

J3304 vs J3299: what is the difference?

Both are HCPCS Level II codes whose descriptor names triamcinolone acetonide. What sets J3299 apart: Xipere from Bausch & Lomb Americas Inc. J3304 is billed per 1 mg, limit $19.159, MUE 64; J3299 is billed per 1 mg, limit $47.705, MUE 72. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.